Publication:
Carbonic Anhydrase Inhibitors: Inhibition of Human and Bovine Isoenzymes by Benzenesulphonamides, Cyclitols and Phenolic Compounds

dc.authorscopusid23027537500
dc.authorscopusid6506852287
dc.authorscopusid6603488994
dc.authorscopusid23013520200
dc.authorscopusid7102904152
dc.contributor.authorEkinci, D.
dc.contributor.authorKurbanoǧlu, N.I.
dc.contributor.authorSalamci, E.
dc.contributor.authorŞentürk, M.
dc.contributor.authorSupuran, C.T.
dc.date.accessioned2020-06-21T14:17:12Z
dc.date.available2020-06-21T14:17:12Z
dc.date.issued2012
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Ekinci] Deniz, Department of Agricultural Biotechnology, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Kurbanoǧlu] Namudar Izzet, Department of Science Education, Sakarya Üniversitesi, Serdivan, Sakarya, Turkey; [Salamci] Emine, Department of Chemistry, Atatürk Üniversitesi, Erzurum, Erzurum, Turkey; [Şentürk] Murat, Department of Chemistry, Aǧrı İbrahim Çeçen Üniversitesi, Agri, Agri, Turkey; [Supuran] Claudiu T., Laboratorio di Chimica Bioinorganica, Università degli Studi di Firenze, Florence, FI, Italyen_US
dc.description.abstractCarbonic anhydrase inhibitors (CAIs) are a class of pharmaceuticals used as anti-glaucoma agents, diuretics and anti-epileptics. We report here the inhibitory capacities of benzenesulphonamides, cyclitols and phenolic compounds 1-11 against three human CA isozymes (hCA I, hCA II and hCA VI) and bovine skeletal muscle carbonic anhydrase III (bCA III). The four isozymes showed quite diverse inhibition profiles with Ki values ranging from low micromolar to millimolar concentrations against all isoenzymes. Compound 5 and 6 had more powerful inhibitory action against hCA I and very similar action against hCA II and hCA VI as compared with acetazolamide (AZA) and sulphapyridine (SPD), specific CAIs. Probably the inhibition mechanism of the tested compounds is distinct of the sulphonamides with RSO<inf>2</inf>NH<inf>2</inf> groups and similar to that of the coumarins/lacosamide, i.e. binding to a distinct part of the active site than that where sulphonamides bind. These data may lead to drug design campaigns of effective CAIs possessing a diverse inhibition mechanism compared to other sulphonamide/sulphamate inhibitors. © 2012 Informa UK, Ltd.en_US
dc.identifier.doi10.3109/14756366.2011.621122
dc.identifier.endpage848en_US
dc.identifier.issn1475-6366
dc.identifier.issn1475-6374
dc.identifier.issue6en_US
dc.identifier.pmid21999604
dc.identifier.scopus2-s2.0-84870543839
dc.identifier.scopusqualityQ1
dc.identifier.startpage845en_US
dc.identifier.urihttps://doi.org/10.3109/14756366.2011.621122
dc.identifier.volume27en_US
dc.identifier.wosWOS:000311682500010
dc.identifier.wosqualityQ1
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofJournal of Enzyme Inhibition and Medicinal Chemistryen_US
dc.relation.journalJournal of Enzyme Inhibition and Medicinal Chemistryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBenzenesulphonamideen_US
dc.subjectCarbonic Anhydraseen_US
dc.subjectCyclitolen_US
dc.subjectGlaucomaen_US
dc.subjectInhibitionen_US
dc.titleCarbonic Anhydrase Inhibitors: Inhibition of Human and Bovine Isoenzymes by Benzenesulphonamides, Cyclitols and Phenolic Compoundsen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files